NORETHIN 1/35E-21 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Norethin 1/35e-21, and when can generic versions of Norethin 1/35e-21 launch?
Norethin 1/35e-21 is a drug marketed by Watson Pharms Teva and is included in one NDA.
The generic ingredient in NORETHIN 1/35E-21 is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NORETHIN 1/35E-21?
- What are the global sales for NORETHIN 1/35E-21?
- What is Average Wholesale Price for NORETHIN 1/35E-21?
Summary for NORETHIN 1/35E-21
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 7 |
| Patent Applications: | 131 |
| DailyMed Link: | NORETHIN 1/35E-21 at DailyMed |
US Patents and Regulatory Information for NORETHIN 1/35E-21
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Pharms Teva | NORETHIN 1/35E-21 | ethinyl estradiol; norethindrone | TABLET;ORAL-21 | 071480-001 | Apr 12, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
